Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 20

1.

Campath, calcineurin inhibitor reduction and chronic allograft nephropathy (3C) study: background, rationale, and study protocol.

Haynes R, Baigent C, Harden P, Landray M, Akyol M, Asderakis A, Baxter A, Bhandari S, Chowdhury P, Clancy M, Emberson J, Gibbs P, Hammad A, Herrington W, Jayne K, Jones G, Krishnan N, Lay M, Lewis D, Macdougall I, Nathan C, Neuberger J, Newstead C, Pararajasingam R, Puliatti C, Rigg K, Rowe P, Sharif A, Sheerin N, Sinha S, Watson C, Friend P; 3C Study Collaborative Group..

Transplant Res. 2013 May 6;2(1):7. doi: 10.1186/2047-1440-2-7.

2.
3.

Calcineurin inhibitor-sparing regimens in solid organ transplantation: focus on improving renal function and nephrotoxicity.

Flechner SM, Kobashigawa J, Klintmalm G.

Clin Transplant. 2008 Jan-Feb;22(1):1-15. doi: 10.1111/j.1399-0012.2007.00739.x. Review.

PMID:
18217899
4.

Treatment strategies to minimize or prevent chronic allograft dysfunction in pediatric renal transplant recipients: an overview.

Höcker B, Tönshoff B.

Paediatr Drugs. 2009;11(6):381-96. doi: 10.2165/11316100-000000000-00000. Review.

PMID:
19877724
5.

Calcineurin inhibitor-free immunosuppression in pediatric renal transplantation: a viable option?

Höcker B, Tönshoff B.

Paediatr Drugs. 2011 Feb 1;13(1):49-69. doi: 10.2165/11538530-000000000-00000. Review.

PMID:
21162600
6.

Belatacept for kidney transplant recipients.

Masson P, Henderson L, Chapman JR, Craig JC, Webster AC.

Cochrane Database Syst Rev. 2014 Nov 24;(11):CD010699. doi: 10.1002/14651858.CD010699.pub2. Review.

PMID:
25416857
7.

Minimizing calcineurin inhibitor drugs in renal transplantation.

Flechner SM.

Transplant Proc. 2003 May;35(3 Suppl):118S-121S. Review.

PMID:
12742481
8.

Steroid and calcineurin inhibitor-sparing protocols in kidney transplantation.

Helal I, Chan L.

Transplant Proc. 2011 Mar;43(2):472-7. doi: 10.1016/j.transproceed.2011.01.054. Review.

PMID:
21440737
9.

Clinical and cost-effectiveness of newer immunosuppressive regimens in renal transplantation: a systematic review and modelling study.

Woodroffe R, Yao GL, Meads C, Bayliss S, Ready A, Raftery J, Taylor RS.

Health Technol Assess. 2005 May;9(21):1-179, iii-iv. Review.

10.

Immunosuppression in simultaneous pancreas-kidney transplantation: progress to date.

Heilman RL, Mazur MJ, Reddy KS.

Drugs. 2010 May 7;70(7):793-804. doi: 10.2165/11535430-000000000-00000. Review.

PMID:
20426494
11.
12.

Calcineurin inhibitor-free protocols: risks and benefits.

Barbari AG, Stephan AG, Masri MA.

Saudi J Kidney Dis Transpl. 2007 Mar;18(1):1-23. Review.

13.

Pathogenesis and management of chronic allograft nephropathy.

Yilmaz S, Sar A.

Drugs. 2008;68 Suppl 1:21-31. Review.

PMID:
18442298
14.

A systematic review and economic model of the clinical and cost-effectiveness of immunosuppressive therapy for renal transplantation in children.

Yao G, Albon E, Adi Y, Milford D, Bayliss S, Ready A, Raftery J, Taylor RS.

Health Technol Assess. 2006 Dec;10(49):iii-iv, ix-xi, 1-157. Review.

15.

Cordyceps sinensis (a traditional Chinese medicine) for kidney transplant recipients.

Hong T, Zhang M, Fan J.

Cochrane Database Syst Rev. 2015 Oct 12;(10):CD009698. doi: 10.1002/14651858.CD009698.pub2. Review.

PMID:
26457607
16.

Calcineurin inhibitor sparing with mycophenolate in kidney transplantation: a systematic review and meta-analysis.

Moore J, Middleton L, Cockwell P, Adu D, Ball S, Little MA, Ready A, Wheatley K, Borrows R.

Transplantation. 2009 Feb 27;87(4):591-605. doi: 10.1097/TP.0b013e318195a421. Review.

PMID:
19307799
17.

Calcineurin inhibitor sparing strategies in renal transplantation, part one: Late sparing strategies.

Mathis AS, Egloff G, Ghin HL.

World J Transplant. 2014 Jun 24;4(2):57-80. doi: 10.5500/wjt.v4.i2.57. Review.

18.

Calcineurin inhibitor-free immunosuppression in kidney transplantation.

Guerra G, Srinivas TR, Meier-Kriesche HU.

Transpl Int. 2007 Oct;20(10):813-27. Review.

19.

High-Throughput Proteomic Approaches to the Elucidation of Potential Biomarkers of Chronic Allograft Injury (CAI).

Cassidy H, Slyne J, Frain H, Slattery C, Ryan MP, McMorrow T.

Proteomes. 2013 Sep 23;1(2):159-179. doi: 10.3390/proteomes1020159. Review.

20.

Chronic allograft injury: Mechanisms and potential treatment targets.

Riella LV, Djamali A, Pascual J.

Transplant Rev (Orlando). 2017 Jan;31(1):1-9. doi: 10.1016/j.trre.2016.10.005. Review.

PMID:
27847221

Supplemental Content

Support Center